CY1122530T1 - Θεραπευτικος παραγων ή προφυλακτικος παραγων για ανοια - Google Patents
Θεραπευτικος παραγων ή προφυλακτικος παραγων για ανοιαInfo
- Publication number
- CY1122530T1 CY1122530T1 CY20191101311T CY191101311T CY1122530T1 CY 1122530 T1 CY1122530 T1 CY 1122530T1 CY 20191101311 T CY20191101311 T CY 20191101311T CY 191101311 T CY191101311 T CY 191101311T CY 1122530 T1 CY1122530 T1 CY 1122530T1
- Authority
- CY
- Cyprus
- Prior art keywords
- paragon
- dementia
- preventive
- therapy
- ser413
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 | ||
| PCT/JP2013/065090 WO2013180238A1 (ja) | 2012-05-31 | 2013-05-30 | 認知症治療剤又は予防剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122530T1 true CY1122530T1 (el) | 2021-01-27 |
Family
ID=49673425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101311T CY1122530T1 (el) | 2012-05-31 | 2019-12-13 | Θεραπευτικος παραγων ή προφυλακτικος παραγων για ανοια |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (enExample) |
| EP (2) | EP2857039B1 (enExample) |
| JP (3) | JP5971659B2 (enExample) |
| KR (2) | KR102133610B1 (enExample) |
| CN (1) | CN104602708B (enExample) |
| AR (1) | AR091218A1 (enExample) |
| AU (2) | AU2013268364B2 (enExample) |
| BR (1) | BR112014029566A2 (enExample) |
| CA (1) | CA2875205C (enExample) |
| CY (1) | CY1122530T1 (enExample) |
| DK (1) | DK2857039T3 (enExample) |
| ES (2) | ES2763361T3 (enExample) |
| HR (1) | HRP20192267T1 (enExample) |
| HU (1) | HUE046919T2 (enExample) |
| IL (1) | IL235899B (enExample) |
| LT (1) | LT2857039T (enExample) |
| ME (1) | ME03587B (enExample) |
| MX (1) | MX361128B (enExample) |
| MY (1) | MY172458A (enExample) |
| NZ (1) | NZ630536A (enExample) |
| PH (1) | PH12014502669B1 (enExample) |
| PL (1) | PL2857039T3 (enExample) |
| PT (1) | PT2857039T (enExample) |
| RS (1) | RS59802B1 (enExample) |
| RU (1) | RU2657438C2 (enExample) |
| SG (2) | SG10201805410XA (enExample) |
| SI (1) | SI2857039T1 (enExample) |
| TW (2) | TWI700296B (enExample) |
| WO (1) | WO2013180238A1 (enExample) |
| ZA (1) | ZA201409186B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8703137B2 (en) | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| EP2709728B1 (en) * | 2011-05-20 | 2019-01-23 | Oligomerix, Inc. | Tau protease methods of use |
| BR112014029566A2 (pt) * | 2012-05-31 | 2017-07-25 | Univ Osaka City | agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo |
| JP6345655B2 (ja) | 2012-07-03 | 2018-06-20 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | タウに対する抗体 |
| TW202136296A (zh) * | 2014-06-27 | 2021-10-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| CN109791149A (zh) * | 2016-09-30 | 2019-05-21 | 豪夫迈·罗氏有限公司 | 用于功能分析多特异性分子的基于spr的双重结合测定法 |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| BR112019022789A2 (pt) | 2017-05-30 | 2020-06-09 | Teijin Pharma Ltd | anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, molécula de ácido nucleico, vetor de clonagem ou vetor de expressão, célula recombinante, processo de produção de um anticorpo do receptor de anti-igf-i ou fragmento do mesmo ou um derivado do mesmo, composição farmacêutica, medicamento, método para cultivar células derivadas de vertebrados in vitro, e, animal transgênico. |
| MA50629A (fr) | 2017-10-02 | 2021-03-31 | Merck Sharp & Dohme | Composés monobactames de chromane pour le traitement d'infections bactériennes |
| NZ762251A (en) | 2017-10-16 | 2025-12-19 | Eisai R&D Man Co Ltd | Anti-tau antibodies and uses thereof |
| US11667707B2 (en) | 2018-04-06 | 2023-06-06 | Teijin Pharma Limited | SPNS2 neutralizing antibody |
| CN112469827B (zh) * | 2018-07-04 | 2024-05-24 | 学校法人爱知医科大学 | 控制Tau的剪接的反义寡核苷酸及其用途 |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| JP7429404B2 (ja) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | タウ関連疾患モデルの製造方法 |
| EP4040153A4 (en) | 2019-09-30 | 2023-07-26 | Nipro Corporation | PROCEDURE FOR DETECTING TAU PROTEIN USING A BLOOD SAMPLE AS SAMPLE |
| JP2023518281A (ja) | 2020-03-19 | 2023-04-28 | ヴァスキュラー バイオサイエンスィズ | コロナウイルス生存率改善のためのｃａｒペプチド |
| EP4171633A1 (en) * | 2020-06-25 | 2023-05-03 | Merck Sharp & Dohme LLC | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN120019071A (zh) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | Tau结合化合物 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| CA2655634A1 (en) * | 2006-06-16 | 2007-12-27 | Envivo Pharmaceuticals, Inc. | Transgenic flies expressing tau and amyloid precursor fragment |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CA3239368A1 (en) | 2009-06-10 | 2010-12-16 | New York University | Immunological targeting of pathological tau proteins |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US8703137B2 (en) * | 2011-01-31 | 2014-04-22 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (tr) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Bağlantısız hareketli ürün reklam standı. |
| BR112014029566A2 (pt) * | 2012-05-31 | 2017-07-25 | Univ Osaka City | agente terapêutico ou agente profilático para desordens cognitivas, anticorpo monoclonal, anticorpo para proteína tau fosforilada, e, peptídeo |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
-
2013
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502669B1 (en) | Therapeutic agent or prophylactic agent for dementia | |
| CY1123865T1 (el) | Τροποποιηση της εξειδικευσης δομημενου πολυπεπτιδιου | |
| CY1122826T1 (el) | Προ-συντηξης rsv f αντιγονα | |
| CY1119766T1 (el) | Νεοι ρυθμιστες κινασης βενζοπυρανιου | |
| CY1122676T1 (el) | Αντισωματα εναντι της κλαυδινης 18.2 που ειναι χρησιμα στη διαγνωση του καρκινου | |
| CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
| CY1122458T1 (el) | Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων | |
| CY1121170T1 (el) | Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων | |
| CY1124428T1 (el) | Αντισωματα και προσδιορισμοι για την ανιχνευση του υποδοχεα φυλλικου οξεος 1 | |
| PH12017501417A1 (en) | Anti-fap antibodies and methods of use | |
| CY1120729T1 (el) | Πεπτιδια και συνθεσεις για τη θεραπεια τραυματισμου των αρθρωσεων | |
| CY1120246T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
| CY1123690T1 (el) | Ειδικα για cd40l ικριωματα που προερχονται απο τν3 και μεθοδοι χρησεως αυτων | |
| NZ730763A (en) | Methods of treating a tauopathy | |
| IN2014MN01642A (enExample) | ||
| BR112013020500A8 (pt) | anticorpo isolado, recombinante ou purificado | |
| MA39248B1 (fr) | Anticorps anti-jagged1 et procédés d'utilisation correspondants | |
| MY160552A (en) | Low protein infant formula with increased essential amino acids | |
| IN2014DN05885A (enExample) | ||
| EA201490778A1 (ru) | АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ | |
| NZ626242A (en) | Anti-asic1 antibodies and uses thereof | |
| WO2014144721A3 (en) | Treating th2-mediated diseases by inhibition of bromodomain-comprising proteins brd7 and brd9 | |
| CY1120132T1 (el) | Χρηση ρ3 πρωτεϊνων συντηξης βακτηριοφαγου ως παραγοντων δεσμευσης αμυλοειδους | |
| FR2968561B1 (fr) | Utilisation d'un anticorps dirige contre une proteine membranaire | |
| CY1118967T1 (el) | Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης |